Restoring Lives
One Story At A Time

We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More

In the News

April 1, 2019

Assertio Therapeutics Announces Appointment of Jay Galeota to Board of DirectorsRead More

March 28, 2019

Assertio Therapeutics Announces Favorable NUCYNTA® Patent RulingRead More

March 6, 2019

Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial ResultsRead More

More News